<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/99892">
      <dc:title>Safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients</dc:title>
      <dc:creator>van Bohemen, Samuel J.</dc:creator>
      <dc:creator>Rogers, Jeffrey M.</dc:creator>
      <dc:creator>Alavanja, Aleksandra</dc:creator>
      <dc:creator>Evans, Andrew</dc:creator>
      <dc:creator>Young, Noel</dc:creator>
      <dc:creator>Boughton, Philip C.</dc:creator>
      <dc:creator>Valderrama Valenzuela, Joaquín Tomás</dc:creator>
      <dc:creator>Kyme, Andre Z.</dc:creator>
      <dc:description>This study assessed the safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients. The device captured electroencephalography (EEG) and electrocardiography (ECG) data to compute an ECG-based metric, termed the Electrocardiography Brain Perfusion index (EBPi), which may function as a proxy for cerebral blood flow (CBF). Seventeen ischaemic stroke patients wore the device for nine hours and reported feedback at 1, 3, 6 and 9 h regarding user experience, comfort, and satisfaction (acceptability). Safety was assessed as the number of adverse events reported. Feasibility was assessed as the percentage of uninterrupted EEG/ECG data recorded (data capture efficiency). No adverse events were reported, only minor incidences of discomfort. Overall device comfort (mean ± 1 standard deviation (SD) (range)) (92.5% ± 10.3% (57.0–100%)) and data capture efficiency (mean ± 1 SD (range)) (95.8% ± 6.8% (54.8–100%)) were very high with relatively low variance. The device didn’t restrict participants from receiving clinical care and rarely (n = 6) restricted participants from undertaking routine tasks. This study provides a promising evidence base for the deployment of the device in a clinical setting. If clinically validated, EBPi may be able to detect CBF changes to monitor early neurological  deterioration and treatment outcomes, thus filling an important gap in current monitoring options.</dc:description>
      <dc:date>2025-01-22T08:37:49Z</dc:date>
      <dc:date>2025-01-22T08:37:49Z</dc:date>
      <dc:date>2024-07</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>van Bohemen SJ, Rogers JM, Alavanja A, Evans A, Young N, Boughton PC, Valderrama JT, Kyme AZ. Safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients. Journal of Medical Enginering &amp; Technology (2024) 48, 173-185. doi: 10.1080/03091902.2024.2409115.</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/99892</dc:identifier>
      <dc:identifier>10.1080/03091902.2024.2409115</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>Taylor and Francis</dc:publisher>
   </ow:Publication>
</rdf:RDF>